Palatin Technologies Inc (LTS:0KF3)
$ 1.1216 0.0122 (1.1%) Market Cap: 22.48 Mil Enterprise Value: 20.57 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 50/100

Palatin Technologies Inc To Discuss PL9643 Phase 3 Clinical Study Results Transcript

Feb 28, 2024 / 01:30PM GMT
Release Date Price: $2.52 (-32.15%)
Operator

Greetings and welcome to Palatin's PL. 96 for three Phase three clinical study results conference call. At this time, all participants are in a listen only mode. A question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. As a reminder, this conference call is being recorded.

Before we begin our remarks, I would like to remind you that statements made by Palatin are not historical facts and may be forward-looking statements. These statements are based on assumptions that may or may not prove to be accurate and that the actual results may differ materially from those anticipated due to the variety of risks and uncertainties discussed in the Company's most recent filings with the Securities and Exchange Commission. Please consider such risks and uncertainties carefully in evaluating these forward-looking statements made by Palatin's prospect.

Now I would like to turn the call over to our host, Dr. Carl Spana, President and Chief Executive Officer of Palatin. Please go

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot